US › Healthcare

InflaRx N.V. (IFRX)

US · Healthcare · Biotechnology

$2.06+0.98%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-10.6M

EPS

$-0.11

EPS estimate

$-0.08

EPS came in at -0.11 against a street estimate of -0.08 — a miss of 37.5%.

Key statistics

Market cap

$308.0M

Forward P/E

0.0

P/B

1.80

Book value

$1.15

EPS (TTM)

$-0.58

52-week high

$2.95

52-week low

$0.80

50-day MA

$2.00

200-day MA

$1.52

Beta

2.54

Analyst view

Analysts rate InflaRx N.V. a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $7.93.

Shareholding

Insiders

2.95%

Institutions

70.34%

Largest institutional holders

Fund	Stake
TCG Crossover Management, LLC	9.84%
Suvretta Capital Management, LLC	5.38%
Spruce Street Capital LP	3.63%
683 Capital Management LLC	2.25%
Great Point Partners LLC	2.07%
Squadron Capital Management LLC	1.36%
Bank of America Corp	1.34%
Eversept Partners, LP	0.88%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for InflaRx N.V. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.